{"id":"c03b764a-622a-5d24-8611-02d948cc5b0a","stable_key":"44eaeae5-557a-552b-8998-884f30462e2a:sulforaphane-cyp3a4-rifampicin-null","predicate":"did_not_prevent_rifampicin_induction_of","statement":"Coadministration did not prevent rifampicin-driven CYP3A induction; rifampicin alone lowered midazolam AUC by 70%.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"e5a7ccd4-06ee-5d3d-9a75-68efee165971","mechanism_event_label":"The proposed receptor-blocking effect from laboratory work did not carry through in the human trial.","subject":{"id":"67e70215-70c4-546a-84b4-0819fac0b326","slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"},"object":{"id":"4df69614-d899-5299-a999-e891f6298c10","slug":"cyp3a4-activity","display_name":"Human CYP3A4 activity, probe and compartment specified","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e5a7ccd4-06ee-5d3d-9a75-68efee165971","stable_key":"44eaeae5-557a-552b-8998-884f30462e2a:sulforaphane-cyp3a4-rifampicin-null-event","event_type":"biochemical_relationship","label":"The proposed receptor-blocking effect from laboratory work did not carry through in the human trial.","description":"Coadministration did not prevent rifampicin-driven CYP3A induction; rifampicin alone lowered midazolam AUC by 70%.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"54e95ff1-4ffa-5e6f-a4cb-b47e5d2a5bda","slug":"cyp3a4","display_name":"Human cytochrome P450 3A4","entity_type_key":"protein"},"role":"phenotyped_enzyme","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d9c26ae7-877e-5c95-a6b4-b0ea07cf638d","slug":"midazolam-exposure","display_name":"Midazolam plasma exposure / AUC","entity_type_key":"cellular_process"},"role":"probe_readout","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"67e70215-70c4-546a-84b4-0819fac0b326","slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"4df69614-d899-5299-a999-e891f6298c10","slug":"cyp3a4-activity","display_name":"Human CYP3A4 activity, probe and compartment specified","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/sulforaphane-research/23153560.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec\", \"start_char\": 0, \"end_char\": 1664, \"text_sha256\": \"e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Three-arm randomized crossover trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Rifampicin 300 mg/day, with or without sulforaphane 450 micromol/day for seven days; sulforaphane alone","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Average null result does not exclude individual or other-drug interactions; high-baseline subgroup finding is not a dosing rule.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Sulforaphane research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human, 24 healthy adults; humanized-PXR mouse parallel study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The proposed receptor-blocking effect from laboratory work did not carry through in the human trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[sulforaphane-p23153560] Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. (2013). https://pubmed.ncbi.nlm.nih.gov/23153560/ DOI: 10.1016/j.taap.2012.10.029","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"CYP3A phenotyping with midazolam","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7ceb0ed7-4328-5445-81ad-a81edb3d8183","evidence_kind":"source_excerpt","locator":"Lines 1256-1267","start_line":1256,"end_line":1267,"excerpt":"### sulforaphane-cyp3a4-rifampicin-null\nCoadministration did not prevent rifampicin-driven CYP3A induction; rifampicin alone lowered midazolam AUC by 70%.\nCondition category: normal\nnutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The proposed receptor-blocking effect from laboratory work did not carry through in the human trial.\norganism: Human, 24 healthy adults; humanized-PXR mouse parallel study\ntissue_or_cell_type: CYP3A phenotyping with midazolam\nexperimental_model: Three-arm randomized crossover trial\nlimitations: Average null result does not exclude individual or other-drug interactions; high-baseline subgroup finding is not a dosing rule.\nexposure: Rifampicin 300 mg/day, with or without sulforaphane 450 micromol/day for seven days; sulforaphane alone\nevidence_span: {\"source_cache\": \"artifacts/sulforaphane-research/23153560.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec\", \"start_char\": 0, \"end_char\": 1664, \"text_sha256\": \"e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec\"}\n[sulforaphane-p23153560] Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. (2013). https://pubmed.ncbi.nlm.nih.gov/23153560/ DOI: 10.1016/j.taap.2012.10.029","model_system":"Three-arm randomized crossover trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [sulforaphane-p23153560] Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. (2013). https://pubmed.ncbi.nlm.nih.gov/23153560/ DOI: 10.1016/j.taap.2012.10.029","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a4bafbf7-f117-53c9-a6d7-8fb25e4aca72","stable_key":"import-44eaeae5-557a-552b-8998-884f30462e2a","title":"Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f355c492a6c35673d8260b1328667fe206e5315b9fcaa5aeff53d80373c7ef97","revision_id":"f2c47d71-34cd-5160-8e92-fe196b576707","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}